Explore the words cloud of the 3DCC project. It provides you a very rough idea of what is the project "3DCC" about.
The following table provides information about the project.
STEMTEK THERAPEUTICS SL
|Coordinator Country||Spain [ES]|
|Total cost||71˙429 €|
|EC max contribution||50˙000 € (70%)|
1. H2020-EU.3.1.3. (Treating and managing disease)
|Duration (year-month-day)||from 2016-12-01 to 2017-04-30|
Take a look of project's partnership.
|1||STEMTEK THERAPEUTICS SL||ES (DERIO)||coordinator||50˙000.00|
StemTek is a global biopharmaceutical company with a clear stem cell focus in drug development for cancer treatment. Only about 10% of the candidate compounds progress successfully through clinical development. Many drugs fail during clinical trials, especially during phase III, which is the most expensive phase of clinical development, largely due to the lack of clinical efficacy and/or unacceptable toxicity.
StemTek is developing a solution to make cell based assays a commodity: easy to get, easy to buy, easy to use, and disposable, so we eliminate the need for large tissue culture facilities. This new solution is a ready-to-use 3D spheroid culture in standard 96 well plate format that allows customers to profile their pipeline of compounds for their effect on CSC populations using 3D culture models.
Thanks to the 3DCC, a business opportunity appears to develop a multi-million euro business capitalizing on the thriving interest from Pharma in finding novel biological testing systems based on 3D cell culture. Latest Markets&market report (2016) establishes that the global 3D cell culture market is expected to reach USD 1,345.2 M by 2021 from USD 466.8 M in 2016 at a CAGR of 23.6% (market growth). According to BCC research, from the seven different niches, “Reagents, media and sera” is precisely the most relevant (37.2 %). 3DCC objectives are: • To produce tailor made kits to improve compatibility with different drug development programs, leading to a broad range of applications. • To use all the competitive advantages of CSC enriched 3D spheroid cultures in ready to use standard 96 well plate format. • The large-scale production of ready to use kits to be able to enter/supply the pharmaceutical industry to achieve economies of scale, and go from current 800 kits/year (manually) up to 120.000 kits per year. • The integration of CSC testing into the drug development strategy of top 10 Big Pharma companies.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "3DCC" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "3DCC" are provided by the European Opendata Portal: CORDIS opendata.
Focused Ultrasound and RadioTHERapy for Noninvasive Palliative Pain Treatment in Patients with Bone MetastasisRead More
Translational studies of HEAD and neck cancer in South America and EuropeRead More
BETTER TREATMENTS FOR BREATHLESSNESS IN PALLIATIVE AND END OF LIFE CARERead More